Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Zhenzhou, China Clinical Trials

A listing of Zhenzhou, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (7) clinical trials

A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients

Randomised, double-blind, parallel group study to compare PK and PD profiles between IBI301 and rituximab in patients with CD20+ B-cell Lymphoma

Phase

0.0 miles

Learn More »

BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma

Primary Objectives To determine the feasibility ad safety of BCMA CAR-T cells in treating patients with multiple myeloma. To determine in vivo dynamics and persistency of BCMA CAR-T cells. To access the efficacy of BCMA CAR-T cells in patients with multiple myeloma. Secondary Objectives To assess the bone marrow and ...

Phase

0.0 miles

Learn More »

Pharmacokinetics Efficacy and Safety of the 304 Injection

This is a multi-center, randomized, double-blind, parallel controlled, single-dose study to evaluate the pharmacokinetic, safety and efficacy of 304 injection compared with rituximab injection. To avoid the impact of tumor burden on pharmacokinetics, this study will be conducted in CD20 positive B-cell non-Hodgkin lymphoma patients who have achieved CR/CRu status ...

Phase

0.79 miles

Learn More »

Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma

Although CAR19 T cell therapy brings hope, the patients with refractory/relapsed B-cell lymphoma is still a problem for the current treatment. There are still some patients with poor therapeutic efficacy, and the efficacy of CAR19-T cell therapy remains to be improved. Basic research shows that there is a synergistic effect ...

Phase

2.42 miles

Learn More »

BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma

There are no effective regimens for relapsed/refractory myeloma. BCMA express extensively in mature B cells and plasma cells. Myeloma cells express BCMA universally. BCMA signal pathway can induce plasma cell proliferation and survival, down-regulation of BCMA could control the progression of myeloma. The BCMA CAR used in this study consists ...

Phase

2.42 miles

Learn More »

CD7 CAR-T Cells for Patients With Relapse/Refractory CD7+ NK/T Cell Lymphoma and T-lymphoblastic Lymphoma

This study is designed to explore the safety and efficacy of CD7 CAR-T Cells for patients with relapse/refractory CD7+ NK/T cell lymphoma and T-lymphoblastic lymphoma, and to evaluate the pharmacokinetics of CD7 CAR-T cells in patients.

Phase

2.42 miles

Learn More »

A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration

This is a multicenter, open-label study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of multiple intravitreal injection TK001 in patients with AMD. It consists of core study (12 weeks) and extension study (40 weeks). In the core study, patients will receive their assigned dose in a 50-L solution ...

Phase

3.83 miles

Learn More »